Stocks making the biggest moves midday: SpaceX, GE Vernova, Crinetics Pharmaceuticals, Rivian & more

Midday trading was mixed-to-cautious as AI- and tech-linked names saw large swings: Cognizant gained >6% on an expanded Google Cloud partnership to accelerate Gemini adoption, while GE Vernova fell 10% and semiconductor-related stocks (Micron -5%, Lam Research -7%) slid amid weaker sentiment after Samsung’s mixed results. Regulatory and corporate headlines weighed selectively, with USA Rare Earth down >7% after a WSJ report said lawmakers are expanding a probe into the company’s $1.6B government investment, while Rivian dropped 14% after announcing a major capital raise (75M new shares) alongside guidance above consensus. On deal activity, Vertex agreed to buy Crinetics in a $10B transaction (Crinetics shares roughly doubled) and Fiserv rose >2% on reports it discussed selling its debit payments infrastructure to major U.S. banks.

Analysis

The tape is separating durable AI monetization from AI-adjacent capex names. Software and IT services look like the near-term relative winners because they can sell implementation, workflow integration, and governance without financing new physical capacity; hardware, power, optics, and memory remain the most valuation-sensitive part of the chain and are likely to de-rate further if hyperscaler spending becomes more selective. Second-order: weaker AI-infra sentiment can pressure Korean and Taiwan supply chains, while service-layer vendors that help enterprises operationalize models should see a later-cycle budget reallocation.

The market may be overextending the conclusion from one mixed semiconductor datapoint into a broad AI demand call. The more important catalyst over the next 1-3 months is forward guidance from cloud, memory, and equipment names; if capex plans are merely delayed, the current drawdown in infra proxies could reverse quickly. By contrast, application software faces a slower-burn risk over 6-18 months: AI-native substitutes can compress pricing power, especially where the product is a user-facing content layer rather than a workflow system.

On the special-situations side, the payments asset sale story is more interesting than the headline move: a breakup can surface embedded value if the buyer pool is narrow and regulators do not interfere, but the trade depends on execution and valuation discipline, not the rumor itself. The rare-earth probe is more of a financing/credibility overhang than an immediate operating hit, but it can meaningfully raise the cost of capital for small-cap critical-mineral names if the inquiry expands. Contrarian view: the selloff in AI infrastructure may be too fast, while the market is still underpricing the dispersion within software between commoditizable creative tools and sticky enterprise systems.

Key Decisions for Investors

• Long CTSH / short ADBE for 1-3 months: own the implementation layer that monetizes enterprise AI spend while fading the content-creation layer most exposed to GenAI substitution; stop if ADBE re-accelerates bookings or CTSH fails to convert the Google Cloud narrative into backlog.
• Short MU or LRCX on rallies over the next 2-6 weeks: the risk is another leg lower if memory/wafer capex guides down; cover if the next Samsung/TSMC read-through confirms demand stabilization.
• Long FISV as an event-driven special situation for 3-6 months: asset-sale optionality could re-rate the equity if the process is broad and clean; thesis breaks if bank interest fades or regulators force a discounted structure.
• Avoid chasing GEV/BWXT into weakness; wait for the next earnings guide. If buying AI power exposure, use a tighter-risk call spread instead of cash equity until order visibility improves.
• Watch CRNX/VRTX only as a backfill M&A barometer: the read-through is that strategic buyers still value rare-disease assets, but post-deal multiple risk is low for the acquirer and the real opportunity is elsewhere in the biotech complex.